Introduction:

lung cancer represents the first cause of oncological death in the world. Computed tomography is the most used diagnostic mean to classify the disease by stages.

Objective:

to determine the efficacy of computed tomography in the evaluation of the disease pseudo-progression in patients with non-small cells lung cancer, treated with Cuban immunotherapy.

Materials and methods:

a longitudinal, retrospective, analytical study was conducted in patients with non-small cells lung cancer in advanced stage, treated with Cuban active immunotherapy after the first line of treatment with chemotherapy and chemoradiotherapy, between January 1, 2013 and December 31, 2017. The universe were 91 patients treated with Racotumomab and CIMAvax-EGF. Data were collected from personal clinical records, incorporated in an Excel database and statistically analyzed with the SPSS 23 package.

Results:

28 patients from the total received the Racotumomab vaccine and 63 received the CIMAvax-ECG vaccine. 12.5 % of those treated with Racotumomab and 28 % of those treated with CIMAvax-ECG pseudo progressed. The greatest survival was found in pseudo progressors.

Conclusions:

the computed tomographic studio is efficacious in evaluating the response of the disease pseudo progression in patients with non-small cells lung cancer, treated with Cuban immunotherapy.

        · resumen en Español     · texto en Español     · Español ( pdf )